What is Erste Group Bank's Forecast for NVO FY2027 Earnings?

Key Points

• Erste Group Bank raised its FY2027 EPS forecast for Novo Nordisk to $3.24, up from $3.20, though it remains below the analyst consensus estimate of $3.39.
• Novo Nordisk shares opened at $47.21 and have a consensus “Hold” rating, based on five Buy, fifteen Hold and one Sell recommendation, with an average price target of $65.81.
• The company recently reported quarterly EPS of $0.94 on $11.98 billion in revenue, while investors continue to monitor obesity-drug growth, competitive pressure and execution concerns.

Novo Nordisk A/S (NYSE:NVO - Free Report) - Equities researchers at Erste Group Bank upped their FY2027 earnings per share estimates for Novo Nordisk A/S in a report released on Wednesday, August 5th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $3.24 per share for the year, up from their previous estimate of $3.20. The consensus estimate for Novo Nordisk A/S's current full-year earnings is $3.39 per share.

NVO has been the topic of a number of other reports. HSBC restated a "hold" rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Weiss Ratings upgraded shares of Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday. Nordea Equity Research raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Friday, June 19th. Zacks Research cut shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Monday, July 13th. Finally, BMO Capital Markets reiterated a "market perform" rating and set a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday. Five equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $65.81.

Novo Nordisk A/S Trading Down 0.1%

Shares of NVO stock opened at $47.21 on Monday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The firm has a market capitalization of $210.77 billion, a PE ratio of 11.54, a price-to-earnings-growth ratio of 4.31 and a beta of 0.76. The stock has a fifty day moving average of $47.00 and a two-hundred day moving average of $44.90. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The firm had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.

Hedge Funds Weigh In On Novo Nordisk A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $25,000. Scarborough Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth approximately $26,000. WealthCollab LLC grew its position in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock valued at $27,000 after purchasing an additional 260 shares in the last quarter. Jackson Grant Investment Advisers Inc. purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Quaker Wealth Management LLC increased its stake in Novo Nordisk A/S by 186.0% in the 4th quarter. Quaker Wealth Management LLC now owns 615 shares of the company's stock valued at $31,000 after buying an additional 400 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a $0.5786 dividend. The ex-dividend date of this dividend is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 42.79%.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk raised its full-year sales and profit outlook for the second time this year. Management cited accelerating demand for the Wegovy pill and continued growth in obesity care, while recent coverage noted that second-quarter revenue and earnings exceeded analyst expectations. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: A Texas judge dismissed antitrust claims alleging Novo and Eli Lilly improperly restricted access to compounded GLP-1 weight-loss drugs. The ruling reduces a potential legal overhang for Novo’s obesity-drug business. Lilly and Novo Win a Key GLP-1 Antitrust Fight
• Positive Sentiment: The company declared a dividend of $0.5786 per share for investors of record August 17, payable August 25. The payout may provide some support for income-focused investors, although the reported yield in the announcement appears anomalous.
• Neutral Sentiment: CEO Mike Doustdar and CFO Karina Hertmann are emphasizing a reset in investor expectations and a more disciplined approach to growth after a difficult period. Their comments could help rebuild confidence, but they also underscore pressure to improve execution and regain momentum. Novo Nordisk CEO resets expectations for Wegovy's explosive growth
• Neutral Sentiment: Novo appointed Omnicom as its U.S. media-buying agency of record, a move intended to strengthen marketing for its obesity portfolio but unlikely to materially affect near-term earnings. Novo Nordisk makes Omnicom agency of record for US media buying
• Negative Sentiment: Wegovy pill sales totaled about $497 million, narrowly missing forecasts. Investors remain concerned that the launch is not progressing rapidly enough to offset slowing momentum in Novo’s injectable obesity products. Novo Nordisk CEO addresses investor expectations after Wegovy pill sales miss forecasts
• Negative Sentiment: Eli Lilly’s stronger obesity-drug performance is widening the perceived competitive gap. Analysts also point to U.S. pricing pressure, patent losses, slower product development and pipeline impairments as reasons the raised outlook has not fully changed the negative narrative around Novo’s obesity business. The divide between Eli Lilly and Novo Nordisk is widening

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source